| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a6981ce818b76d571b9676ade452bc5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2020-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87e52dc38fb16604732e23a92d2e77bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e726704a0e330b95b96a2a2813c9492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e472543f3e09b438474cb8b2711c9cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab0b488ff4a98d2f46a1bbc78a8fd78f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c35982bf34fb8818bec7fe2f90ed0d97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c12698842a0f54e5fd2d6cbade09ebc6 |
| publicationDate |
2020-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20200096449-A |
| titleOfInvention |
Pharmaceutical composition for preventing or treating of obesity or fatty liver comprising Fas signal blocking peptides |
| abstract |
The present invention relates to a pharmaceutical composition for the prevention or treatment of obesity, fatty liver, or steatohepatitis comprising a peptide for inhibiting Fas signaling as an active ingredient. The peptide for inhibiting Fas signaling is a Fas which is frequently expressed in liver and adipose tissue during obesity. Because it specifically binds to the inflammatory site due to obesity, the efficiency of transmission to the inflammatory site is high, and the inflammatory response can be suppressed by directly inhibiting the inflammatory response by directly inhibiting Fas signaling, the main signaling system of inflammation, thus improving obesity and non-alcoholic fatty liver Can be used usefully. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023068850-A1 |
| priorityDate |
2018-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |